The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RET rearrangements detected by FISH in “pan-negative” lung adenocarcinoma.
Marileila Varella-Garcia
Honoraria - Abbott Molecular
Research Funding - Abbott Molecular
Liang Guo Xu
No relevant relationships to disclose
Sakshi Mahale
No relevant relationships to disclose
Eamon M Berge
No relevant relationships to disclose
Chiara Bennati
No relevant relationships to disclose
Anh T. Le
No relevant relationships to disclose
Dara Aisner
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Abbott Molecular; Boehringer Ingelheim; Pfizer
Lucio Crinò
No relevant relationships to disclose
Paul A. Bunn
Consultant or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Pfizer; Roche/Genentech; Sanofi
D. Ross Camidge
No relevant relationships to disclose
Robert Charles Doebele
Consultant or Advisory Role - Pfizer
Honoraria - Abbott Molecular
Research Funding - Pfizer